Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Saudi Arabia’s SFDA has approved Leqembi (lecanemab), the Kingdom’s first Alzheimer’s treatment. This innovative drug slows ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others. But patients face a long road to ...

Koenraad Köllmann is bicycling from Portland, Oregon to Portland, Maine, in a powerful message to end the stigma.

Because Leqembi is a Part B drug, not a more common Part D drug, many Medicare patients will owe 20 percent of the cost out-of-pocket. That adds up to more than $5,000 annually.

Leqembi targets the amyloid protein that builds up in the form of plaques in the brains of people with Alzheimer's disease, said Dr. Judith Heidebrink, a neurologist at Michigan Medicine and ...

Eisai spokeswoman Libby Holman said prescriptions for Leqembi have been written, and that the company expects patients to begin receiving the drug soon. It will cost about $26,500 for a year of ...